Australia: Earn-out doesn't immunise against business failure

Key Points:

Business sellers who want to protect their earn-out entitlements should push to ensure that the buyer has minimal room to change or abandon the business.

Porton Down is the UK Government's top secret chemical and biological warfare research facility.

Strangely, it is also a business operation. One of its commercial offshoots was recently involved in a major court case concerning an earn-out provision in a share sale agreement.

The case highlights the importance of precise drafting in earn-outs.

Trial and error

A Porton Down company developed BacLite, a new test for staphylococcus aureus (aka golden staph). BacLite was intended to overcome financial and operational issues that affected other commercial tests for golden staph.

After successful trials in the UK and sales to a few hospitals, the company was sold to 3M in February 2007.

The purchase price consisted of an upfront payment of £10.4m and an earn-out payment equal to the net sales of the product in calendar year 2009. The earn-out clause obliged 3M to "diligently seek" regulatory approval outside of the EU and to "actively market" BacLite. The sale agreement also required 3M to keep the company in business unless the sellers agreed otherwise (such agreement not to be unreasonably withheld).

FDA approval was needed in order to sell BacLite in the USA.

To that end, 3M began initial US trials in June 2007. By November 2007, it was clear that the US tests were producing quite different (and more disappointing) results from those in the UK.

3M decided to put the trials on hold while the problem was investigated. At the same time, 3M's senior management began to seriously consider pulling the pin on the product in the US. Despite eventually understanding the reasons for the poor results (mostly problems with the design of the clinical studies), no further efforts were made to obtain US approval after June 2008. 3M also wound down its marketing efforts in the EU, and by June 2008 had effectively stopped seeking new customers.

In July and August 2008, 3M was looking to cut its losses. In accordance with the sale agreement, 3M asked the sellers to release it from its ongoing obligations to develop and market BacLite. 3M offered the sellers US$1.1m to settle the matter.

When the sellers refused to accept its offer, 3M decided to act unilaterally. The business was shut down at the end of 2008.

The sellers alleged that 3M had breached the sale agreement in two important respects by not:

  • "diligently" seeking regulatory approval; and
  • "actively" marketing BacLite.

Without those breaches, argued the sellers, BacLite would have achieved sales of $56.45m (£32m) in calendar year 2009.

Perhaps unsurprisingly, the Court held that, once 3M pulled the plug on BacLite (in July 2008), it had breached the sale agreement. What is interesting, however, is the Court's discussion of whether 3M had breached the agreement before that point.

"Diligently seeking" regulatory approval

As noted above, the first clinical trials in the USA (required for FDA approval) did not go according to plan, differing significantly from the results of the UK trials. There were several reasons for this, including:

  • 3M had misunderstood an FDA requirement about the appropriate test against which BacLite was to be compared and, as a result, 3M employed a comparator which was commonly used in the USA (but which was not the same comparator used in the UK trials); and
  • rather than conducting the US trials at precisely the same temperature used in the UK trials, 3M (acting on advice from the scientists who had conducted the UK trials) conducted the US trials within a 2 degree temperature range.

By the time these issues had been identified, 3M was already well on the way to abandoning the business. As a result, it was decided not to conduct new trials or seek FDA approval.

The sellers claimed that the issues with the clinical trial and the abandonment constituted a failure to "diligently" seek FDA approval. They argued that "diligently", in this context, meant to act with reasonable care.

The Court agreed with 3M that the obligation to act diligently was not a high standard of perfection or even any specific standard of expertise, but simply a requirement of reasonable application and industry perseverance. The Court considered that diligently seeking regulatory approval required judgments about which people might reasonably differ.

On that basis, the Court held that 3M had acted diligently. Although misunderstanding the FDA requirements, 3M had trialled BacLite by comparing it with a different comparator and had had no reason to believe that this would produce materially different results from the UK trial. In fact, the UK scientists told 3M that no problems were expected from using the different comparator. Additionally, the temperatures at which the US trials had been conducted were on the basis of advice from the UK scientists that the 2 degree temperature range should be acceptable.

The Court added that, if the sellers had intended that 3M should employ reasonable care, that should have been clearly stated and defined in the sale agreement.

"Actively market"

3M did not recruit a sales force for BacLite until September 2007 (ie. seven months after acquiring it). It did, nevertheless, engage in various marketing activities before that time.

The sellers argued that the delay in recruiting salespeople was a breach of 3M's obligation to "actively" market BacLite, for two reasons:

  • because the earn-out only applied to earnings during calendar year 2009, the obligation to actively market BacLite effectively required 3M to hit the ground running from the moment it acquired the business at the start of 2007; and
  • the meaning of "actively market" was reflected in a sale agreement clause that 3M should devote the same level of resources to marketing BacLite as it devoted to its other products.

In response, 3M argued that:

  • the requirement to "actively" market simply meant that it had to engage in some marketing, rather than none; and
  • its marketing activities before acquiring a salesforce had constituted an "active" marketing effort.

The Court disagreed with 3M on the first point, but agreed with it on the second.

The Court held that "actively" required more than simply taking some steps to go out and sell the product. It certainly required more than simply not being passive. Rather, the marketing efforts viewed overall had to be "characterised by action". The Court recognised that this involves a degree of leeway or a "reasonable margin of appreciation" in terms of the precise action required. So long as 3M acted in good faith with a view to marketing the product successfully in pursuit of the parties' common commercial interest, then that would suffice.

3M had worked hard and put in "considerable and impressive" efforts in marketing up to March 2008. Marketing became more targeted after that point in time, but the Court considered this was still characterised by action.

By June 2008, however, there was no real effort to find new customers (although 3M continued to work on existing customers). 3M was therefore in breach of the sale agreement.

Winning the battle, losing the war

The sellers' victory turned out to be largely symbolic.

Since 3M had stopped marketing the product before calendar year 2009 had even arrived, the Court had to assess the likely level of sales and therefore the amount of the earn-out payment which the sellers should have received.

Looking at all the evidence, it agreed with 3M that BacLite would have been a commercial failure. Apart from the difficulties with the trials, competitor products had been improved to the point where there would have been little market for BacLite.

As a result, the Court concluded that, even if 3M had persisted with the product, sales of no more than US$2.1m would have been likely, giving the plaintiff sellers (who represented about 60% of the original shareholders) an earn-out of US$1.3m (slightly above 3M's original pay-out offer, but well short of the US$33m the sellers were seeking).


This case has important lessons for both sellers and buyers.

As is often the case in contractual disputes, the proof of the pudding is in the drafting. Business sellers who want to protect their earn-out entitlements should push to ensure that the buyer has minimal room to change or abandon the business. Ways in which this might be done include:

  • avoiding vague terms such as "diligently" and "actively" when describing the buyer's obligations, insisting instead on objective tests (eg. prescribing how the key aspects of a clinical test or similar exercise should be conducted):
  • requiring the buyer to provide access to information and business records during the earn out period, to provide the seller with regular reports, and to notify and consult with the seller in relation to key matters; and
  • including a right to buy back the product if the buyer stops supporting it or is not doing a good enough job of developing it.

The message for buyers is more mixed. The case shows that a buyer might be obliged to continue progressing and marketing a product even if the product is a failure. Doing nothing might be a breach of contract, even if that is commercially the most sensible decision. To counter this, a buyer might consider provisions which allow it to stop supporting the business if certain foreseeable events occur (such as, in this case, if trials are unsuccessful or sales are much lower than expected). Buyers could also try to argue for an implied term to this effect.

A pragmatic observer may take the view that, whatever the buyer's legal position, this case shows that the reality is quite different: if the buyer drops the business because it's a commercial dog, any damages award for a broken earn-out clause will be minimal, because the business was never going to be successful anyway.

That pre-emptive approach does suffer from one high-risk fundamental flaw: the court could, with the benefit of hindsight, take a very different view of the future viability of the business.

Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this bulletin. Persons listed may not be admitted in all states and territories.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.